Myconail (Ciclopirox)

Ciclopirox acts by chelating polyvalent metal ions like iron and aluminum, which are essential cofactors for fungal enzymes. This chelation blocks metal‑dependent enzymatic pathways involved in cell membrane synthesis and metabolic processes, leading to disruption of fungal cell integrity and ultimately causing fungal cell death.

The dosage of Myconail is determined by the prescribing clinician based on the type and severity of the infection, the patient’s age, and the area of skin involved. The prescriber will provide specific instructions on how much product to apply, the frequency of application, and the duration of therapy.

Safety data for ciclopirox topical use in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Myconail with their doctor before starting treatment.

To order Myconail, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Myconail (ciclopirox) belongs to a different class than azole or allylamine topical agents. While azoles inhibit ergosterol synthesis, ciclopirox chelates metal ions, offering a distinct mechanism that can be effective against strains resistant to azoles. Clinical choice depends on infection type, resistance patterns, patient tolerance and physician preference.

Myconail should be stored at room temperature, ideally below 25 °C, in its original packaging to protect it from moisture and direct light. Keep the container tightly closed when not in use. Do not freeze the product, and keep it out of reach of children.

Myconail is applied topically to the affected skin area. The prescriber will advise the amount to use, typically a thin layer, and the frequency—often once or twice daily—depending on the infection. The medication should be spread gently and allowed to dry before covering the area with clothing or bandages.

Although uncommon, serious adverse reactions can include severe allergic responses such as angioedema, anaphylaxis, or widespread skin eruptions like Stevens‑Johnson syndrome and toxic epidermal necrolysis. Patients should discontinue use and seek immediate medical attention if they notice signs of a severe reaction, such as extensive rash, swelling, or difficulty breathing.

Myconail should not be used by individuals with a known hypersensitivity to ciclopirox or any of the product’s excipients. It is also contraindicated on broken, severely inflamed, or mucosal skin surfaces. Patients with a history of severe skin reactions to topical medications should consult their healthcare provider before using Myconail.